HCAT

Company Overview — What Does Health Catalyst, Inc. Do?

Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its solutions include a cloud-based data platform, analytics software, and professional services. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. The company was founded in 2008 and is headquartered in South Jordan, Utah. Health Catalyst, Inc. (HCAT) is classified as a micro-cap stock in the Technology sector, specifically within the Computer Software industry. The company is led by CEO Daniel D. Burton and employs approximately 1,200 people. With a market capitalization of $85M, HCAT is one of the notable companies in the Technology sector.

Health Catalyst, Inc. (HCAT) Stock Rating — Avoid (April 2026)

As of April 2026, Health Catalyst, Inc. receives a Avoid rating with a composite score of 23.3/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.HCAT ranks #4,406 out of 4,446 stocks in our coverage universe. Within the Technology sector, Health Catalyst, Inc. ranks #581 of 584 stocks, placing it in the lower half of its Technology peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

HCAT Stock Price and 52-Week Range

Health Catalyst, Inc. (HCAT) currently trades at $1.01. The 52-week high for HCAT is $5.06, which means the stock is currently trading -80.0% from its annual peak. The 52-week low is $1.04, putting the stock -2.9% above its annual trough. Recent trading volume was 629K shares, suggesting relatively thin trading activity.

Is HCAT Overvalued or Undervalued? — Valuation Analysis

Health Catalyst, Inc. (HCAT) carries a value factor score of 12/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.33x, versus the sector average of 3.16x. The price-to-sales ratio is 0.26x, compared to 1.06x for the average Technology stock.

At current multiples, Health Catalyst, Inc. trades at a premium to most Technology peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Health Catalyst, Inc. Profitability — ROE, Margins, and Quality Score

Health Catalyst, Inc. (HCAT) earns a quality factor score of 25/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -41.4%, compared to the Technology sector average of -1.4%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -20.2% versus the sector average of -1.0%.

On a margin basis, Health Catalyst, Inc. reports gross margins of 52.6%, compared to 50.9% for the sector. The operating margin is -28.1% (sector: -0.5%). Net profit margin stands at -32.3%, versus -1.5% for the average Technology stock. Revenue growth is running at 0.5% on a trailing basis, compared to 14.2% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

HCAT Debt, Balance Sheet, and Financial Health

Health Catalyst, Inc. has a debt-to-equity ratio of 62.0%, compared to the Technology sector average of 43.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 1.89x, suggesting adequate working capital coverage. Total debt on the balance sheet is $153M. Cash and equivalents stand at $40M.

HCAT has a beta of 1.27, meaning it is more volatile than the broader market — a $10,000 investment in HCAT would be expected to move 27.1% more than the S&P 500 on any given day. The stability factor score for Health Catalyst, Inc. is 26/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Health Catalyst, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Health Catalyst, Inc. reported revenue of $313M and earnings per share (EPS) of $-2.55. Net income for the quarter was $-102M. Gross margin was 52.6%. Operating income came in at $-88M.

In FY 2025, Health Catalyst, Inc. reported revenue of $311M and earnings per share (EPS) of $-2.55. Net income for the quarter was $-178M. Revenue grew 1.5% year-over-year compared to FY 2024. Operating income came in at $-161M.

In Q3 2025, Health Catalyst, Inc. reported revenue of $76M and earnings per share (EPS) of $-0.32. Net income for the quarter was $-22M. Gross margin was 52.6%. Revenue grew -0.0% year-over-year compared to Q3 2024. Operating income came in at $-18M.

In Q2 2025, Health Catalyst, Inc. reported revenue of $81M and earnings per share (EPS) of $-0.59. Net income for the quarter was $-41M. Revenue grew 6.3% year-over-year compared to Q2 2024. Operating income came in at $-37M.

Over the past 8 quarters, Health Catalyst, Inc. has demonstrated a growth trajectory, with revenue expanding from $76M to $313M. Investors analyzing HCAT stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

HCAT Dividend Yield and Income Analysis

Health Catalyst, Inc. (HCAT) does not currently pay a dividend. This is common among smaller companies in the Computer Software industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Technology dividend stocks may want to explore other Technology stocks or use the stock screener to filter by dividend yield.

HCAT Momentum and Technical Analysis Profile

Health Catalyst, Inc. (HCAT) has a momentum factor score of 12/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 33/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 52/100 reflects moderate short selling activity.

HCAT vs Competitors — Technology Sector Ranking and Peer Comparison

Within the Technology sector, Health Catalyst, Inc. (HCAT) ranks #581 out of 584 stocks based on the Blank Capital composite score. This places HCAT in the lower half of all Technology stocks in our coverage universe. Key competitors and sector peers include IHS Holding Ltd (IHS) with a score of 55.0/100, VERISIGN INC/CA (VRSN) with a score of 56.0/100, ESCO TECHNOLOGIES INC (ESE) with a score of 51.7/100, CareCloud, Inc. (CCLD) with a score of 46.9/100, and MMTec, Inc. (MTC) with a score of 47.4/100.

Comparing HCAT against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full HCAT vs S&P 500 (SPY) comparison to assess how Health Catalyst, Inc. stacks up against the broader market across all factor dimensions.

HCAT Next Earnings Date

No upcoming earnings date has been announced for Health Catalyst, Inc. (HCAT) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy HCAT? — Investment Thesis Summary

The quantitative profile for Health Catalyst, Inc. suggests caution. The quality score of 25/100 flags below-average profitability. The value score of 12/100 indicates premium valuation. Momentum is weak at 12/100, a headwind for near-term performance. High volatility (stability score 26/100) increases portfolio risk.

In summary, Health Catalyst, Inc. (HCAT) earns a Avoid rating with a composite score of 23.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on HCAT stock.

Related Resources for HCAT Investors

Explore more research and tools: HCAT vs S&P 500 comparison, top Technology stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare HCAT head-to-head with peers: HCAT vs IHS, HCAT vs VRSN, HCAT vs ESE.